Patents Examined by Robin L. Teskin
-
Patent number: 4920211Abstract: A functional mutated E1A gene of human adenovirus subgroup B:1 is provided which has a modified autorepression functional domain that is effective to express E1A products that stimulate without net repression of promoters controlling an E1A mutated gene.Type: GrantFiled: January 4, 1988Date of Patent: April 24, 1990Assignee: Vanderbilt UniversityInventors: Clark Tibbetts, Pamela L. Larsen
-
Patent number: 4906474Abstract: A composition of matter suitable for implantation in the body to effect zero order drug release comprising a drug and a polymer of the formula: ##STR1## wherein R and R' can be the same or different and are hydrophobic organic linkages and n and m are integers of 1 or greater.Type: GrantFiled: May 21, 1984Date of Patent: March 6, 1990Assignee: Massachusetts Institute of TechnologyInventors: Robert S. Langer, Howard Rosen, Robert J. Linhardt, Kam Leong
-
Patent number: 4894443Abstract: A novel class of polypeptides of the general formula (F-(Pro).sub.n).sub.m F, wherein F represents a flexible amino acid sequence wherein each amino acid is individually selected from the group consisting of serine, glycine, and threonine, and n is an integer from 4-8 inclusive and m is an integer from 1-4 inclusive, is disclosed. Thses polypeptides are useful in the construction of conjugates between antibodies and peptide toxins. The preparation of such conjugate toxins by linking antibodies to toxin/spacer composites prepared by recombinant techniques is also disclosed.Type: GrantFiled: September 7, 1984Date of Patent: January 16, 1990Assignee: Cetus CorporationInventors: Lawrence I. Greenfield, Donald A. Kaplan, Danute E. Nitecki
-
Patent number: 4879226Abstract: A human physiologically active polypeptide, human Tumor Necrosis Factor (human TNF), comprising a specific amino acid sequence of 155 amino acid residues. The base sequence of the DNA coding for the human TNF has been determined using rabbit TNF cDNA. The human TNF can be advantageously produced on a large scale by recombinant DNA technique. The human TNF of the present invention has been found to be excellent in inducing necrosis of tumors with no toxic effect upon the normal tissues of the living body.Type: GrantFiled: April 6, 1984Date of Patent: November 7, 1989Assignee: Asahi Kasei Kogyo Kabushiki KaishaInventors: Robert B. Wallace, Hirataka Itoh
-
Patent number: 4873189Abstract: Hybrid cell lines which secret monoclonal antibody which is group-specific to bluetongue virus (BTV) antigen and which does not react to antigenically related epizootic hemorrhagic disease virus antigen are disclosed. The antibodies identify BTV in infected cell cultures with immunofluorescence and provide a means for ready diagnosis of BTV in animals.Type: GrantFiled: January 12, 1984Date of Patent: October 10, 1989Assignee: The United States of America as represented by the Secretary of ArgricultureInventors: Michael M. Jochim, Suzanne C. Jones
-
Patent number: 4871661Abstract: Materials can be screened for carcinogenic properties by administering them to test animals and assaying biological tissue, preferably plasma, for the presence of a 60K cancer-associated phosphoprotein. The test is applicable to a wide range of chemically-diverse carcinogens and is not restricted to carcinogens having one particular mode of action.Type: GrantFiled: June 18, 1985Date of Patent: October 3, 1989Assignee: The Ohio State University Research FoundationInventors: Thomas E. Webb, Dorothy E. Schumm, Margaret Hanausek-Walaszek, Zbigniew Walaszek, Raymond W. Lang
-
Patent number: 4870053Abstract: A novel process for the preparation of water-soluble acyl glycoprotein extracted from Klebsiella Pneumoniae containing 30 to 45% by weight of proteins, 30 to 40% by weight of neutral saccharides, less than 4% of glucuronic acid, 2 to 5% by weight of osamines with a molecular weight of about 350,000 daltons and having a polysaccharide chain of n chains of one molecule of glucose and 4 molecules of galactose attached to an asparagine of a proteidic chain by a core formed of heptose and 2-keto-3-deoxy-octulosonic acid followed by an acyl portion containing .beta.-hydroxymyristic acid and then N-acetyl-glucosamine designated herein as F.sub.1 and compositions and a method of inducing antiallergic properties in warm-blooded animals.Type: GrantFiled: January 4, 1984Date of Patent: September 26, 1989Assignee: Roussel UclafInventors: Rene Zalisz, Marie-France Salles
-
Patent number: 4867973Abstract: This invention relates to antibody-therapeutic agent conjugates having a therapeutic agent covalently attached to an antibody or antibody fragment. Also described are methods for intermediates in the preparation of antibody conjugates. Therapeutic in vivo methods utilizing such antibody-therapeutic agent conjugates are described.Type: GrantFiled: September 13, 1984Date of Patent: September 19, 1989Assignee: Cytogen CorporationInventors: John W. F. Goers, Hurley D. King, Chyi Lee, Daniel J. Coughlin, Vernon L. Alvarez, John D. Rodwell, Thomas J. McKearn
-
Patent number: 4816563Abstract: Antigen specific excreted transfer factor may be obtained by collecting material, e.g. colostrum or milk, secreted by the mammary gland of a suitable lactating mammal, e.g. a cow having immunity to the antigen under suitable conditions such that materials which interfere with transfer factor efficacy are removed so as to obtain transfer factor. Colostrum or milk so collected may be used directly, typically after sterilization, or may be treated to further concentrate and/or purify transfer factor. Treatment to yield colostral whey containing transfer factor is presently the preferred method for obtaining transfer factor for use in conferring immunity against diseases associated with antigens for which the transfer factor is specific. Cell-associated transfer factor specific for an antigen may also be obtained by incubation release from, or lysis of, cells obtained from the collected material.Type: GrantFiled: November 15, 1984Date of Patent: March 28, 1989Assignee: Amtron, Inc.Inventors: Gregory B. Wilson, Gary V. Paddock
-
Patent number: 4808537Abstract: A method for isolating and cloning methanol inducible genes from Pichia is taught. The regulatory regions are useful for the methanol regulated expression of heterologous genes.Type: GrantFiled: October 30, 1984Date of Patent: February 28, 1989Assignee: Phillips Petroleum CompanyInventors: David W. Stroman, Paul F. Brust, Steven B. Ellis, Thomas R. Gingeras, Michael M. Harpold, Juerg F. Tschopp
-
Patent number: 4797475Abstract: A composition of matter and method for using the composition of matter to isolate various cell elements from a heterogeneous cell suspension in a simple one step procedure. The composition is a monoclonal antibody mixture including complement and a non-toxic density gradient media. The composition provides a negative selection technique in which undesired subpopulation cells are lysed and separated from the desired cell subpopulation. The invention has particular application to isolation of white cell elements.Type: GrantFiled: July 17, 1985Date of Patent: January 10, 1989Assignee: The Regents of the University of CaliforniaInventors: Paul I. Terasaki, Jimmy Loon, Steven Hardiwidjaja, Nadim El-Awar
-
Patent number: 4792522Abstract: A novel complex designated herein as rigolettone complex is produced by fermentation of Streptomyces aburaviensis strain C-38,242 (ATCC 39290). The complex and its purified bioactive components, jildamycin and mantuamycin, exhibit antitumor activity in mouse tumor systems.Type: GrantFiled: August 22, 1985Date of Patent: December 20, 1988Assignee: Bristol-Myers CompanyInventors: Donald E. Nettleton, Jr., Stanley W. Bray, James A. Bush, William T. Bradner
-
Patent number: 4789633Abstract: Liposomes containing phosphatidylethanolamine, palmitoyl homocysteine or oleic acid or palmitic acid, fuse rapidly when the pH of the medium is reduced below 7. Liposome fusion was measured by (a) mixing of the liposomal lipids as shown by resonance energy transfer, (b) gel filtration and (c) electron microscopy. The presence of phosphatidylethanolamine or acid addition esters thereof in the liposomes greatly enhances fusion; whereas the presence of phosphatidylcholine inhibits fusion. During fusion of liposomes containing phosphatidylethanolamine:palmitoyl homocysteine (8:2), almost all of the encapsulate calcein is released. Inclusion of cholesterol (40%) in the liposomes substantially decreases leakage without impairing fusion. Those pH sensitive liposomes are fused to deliver biologically active molecules such as DNA, into living cells.Type: GrantFiled: April 19, 1984Date of Patent: December 6, 1988Assignee: University of Tennessee Research CorporationInventors: Leaf Huang, Jerome Connor
-
Patent number: 4788059Abstract: A vaccine for immunizing equines against strangles and a method of using the vaccine. The vaccine is made by isolating the causative organism Streptococcus equi (S. equi) from an abscess on a horse showing typical symptoms of strangles, and confirming the identity of the organism through standard biochemical techniques. The isolated S. equi is passed through a suitable growth medium (Todd-Hewitt broth) and two parts per million acriflavine hydrochloride is added. The acriflavine level is increased over a period of approximately eleven weeks to a concentration of about sixteen parts per million to yield an avirulent S. equi while retaining its antigenicity. The method of administering the vaccine consists of inoculating the horse intranasally with the attenuated S. equi.Type: GrantFiled: July 15, 1985Date of Patent: November 29, 1988Assignee: Coopers Animal Health, Inc.Inventor: Myron G. Usdin
-
Patent number: 4782023Abstract: An enzyme conjugate composition comprising an enzyme conjugate, a calcium salt and a polyethylene glycol is disclosed. The enzyme conjugate composition is effectively stabilized by the presence of the calcium salt and the polyethylene glycol.Type: GrantFiled: September 13, 1985Date of Patent: November 1, 1988Assignee: Abbott LaboratoriesInventors: Mark A. Anawis, Roger E. Lindberg
-
Patent number: 4782021Abstract: This invention is a method of producing L-serine by causing glycine to react with formaldehyde by using the culture solution or the microbe cells of a microorganism belonging to the genus Escherichia, having the ability of producing serine hydroxymethyltransferase and not having the practical ability of producing L-serine from glycine alone or enzymatic matter obtained through the treatment of the above culture solution or microbe cells.In this invention, the yield of L-serine can be increased either by carrying out the reaction while maintaining aldehyde concentration at 20 mM or below or by using microbe cells of the aforementioned microorganism after they are caused to contact glycine.Type: GrantFiled: February 5, 1985Date of Patent: November 1, 1988Assignee: Mitsui Toatsu Chemicals, Inc.Inventors: Kenichi Ishiwata, Nobuyoshi Makiguichi, Hideki Kawashima, Tadashi Suzuki, Masami Imadegawa
-
Patent number: 4775630Abstract: A novel alteration of a viral DNA sequence, derived from a human adenovirus type 3 mutant (Ad3) designaed Ad3h15, provides a transcriptional control element which can be used to regulate expression of a selected gene in animal and human cells. The Ad3h15 control element blocks transcription of a controlled gene in the presence of the products of the Ad3 E1A gene, and amplifies transcription in the presence of type 5 (Ad5) adenovirus E1A gene products.Type: GrantFiled: August 15, 1986Date of Patent: October 4, 1988Assignee: Vanderbilt UniversityInventors: Clark Tibbetts, Pamela L. Larsen, Stephen N. Jones, Mary M. McGrane
-
Patent number: 4745064Abstract: The invention relates to a novel microorganism of the genus Rhodococcus, to the use thereof in a process for the microbiological degradation of amino-s-triazines and cyanuric acid in wastewaters, as well as to a process for the microbiological degradation of s-triazine derivatives to biomass or to degradation products such as NH.sup.30.sub.4 and/or chloride, which comprises the combined use of said microorganism with Pseudomonas spp.Type: GrantFiled: October 26, 1984Date of Patent: May 17, 1988Assignee: Ciba-Geigy CorporationInventors: Alasdair M. Cook, Ralf Hutter
-
Patent number: 4742159Abstract: The present invention provides a process for the preparation of digitalis antibodies in which appropriate mammals are immunized with a digoxin bound to protein, the animal serum is obtained, the immune globulin-containing protein fraction is separated in known manner, the immunologically-active globulins are adsorbed on an immunologically-active column and separated from the other proteins, the antibodies are again eluted from the column and the Fab fractions are split with papain and purified, wherein, as immunologically-active adsorbent, there is used an inorganic matrix of large surface area to which digitoxin aldehyde is bound via a spacer which cannot be split with papain and the splitting off of the Fab fraction from the antibodies is carried out on the matrix.The present invention also provides digitalis antibodies obtained by this process, which antibodies can be used for the therapy of digitalis intoxications and for preparing immunological reagents for the determination of digitalis glycosides.Type: GrantFiled: December 19, 1983Date of Patent: May 3, 1988Assignee: Boehringer Mannheim GmbHInventors: Hans-Georg Batz, Herbert Jungfer, Helmut Lenz, Albert Roder
-
Patent number: 4672032Abstract: Methods are provided for the formation of dental enamel crystals in biosynthetic matrix form by the nucleation of calcium solutions with enamel proteins and for the use of such enamel crystals as restorative material.Type: GrantFiled: November 9, 1983Date of Patent: June 9, 1987Assignee: University of Southern CaliforniaInventors: Harold C. Slavkin, Malcolm L. Snead, Savio L. C. Woo, Margarita Zeichner-David